Share ownership Exelixis, Inc.

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:30:00 14/01/2026 am IST			5-day change	1st Jan Change
44.08 ^USD	+0.05%		+3.96%	+0.57%

10:50am	Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM
12/01	Independence, Under Review

Share class: Exelixis, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	27,98,81,450	27,48,71,572 ( 98.21 %)	0	98.21 %

Major shareholders: Exelixis, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.14 %	2,71,85,260	10.14 %	1 192 M $
Vanguard Fiduciary Trust Co. 9.722 %	2,60,64,571	9.722 %	1 142 M $
Farallon Capital Management LLC 7.274 %	1,95,01,500	7.274 %	855 M $
Farallon Capital Management LLC 5.859 %	1,57,09,500	5.859 %	689 M $
Renaissance Technologies LLC 5.766 %	1,54,59,266	5.766 %	678 M $
STATE STREET CORPORATION 4.146 %	1,11,14,815	4.146 %	487 M $
AQR Capital Management LLC 3.424 %	91,81,359	3.424 %	402 M $
Fuller & Thaler Asset Management, Inc. 3.103 %	83,20,794	3.103 %	365 M $
LSV Asset Management 2.898 %	77,68,627	2.898 %	340 M $
Geode Capital Management LLC 2.861 %	76,70,959	2.861 %	336 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	90.46%
Other	6.52%
State Street Corp.	4.15%
Individuals	3.15%
SEI Investments Co.	0.35%
Swedbank AB	0.31%
Schweizerische Nationalbank	0.19%
Governments	0.19%
Hancock Whitney Corp.	0.11%
Danske Bank A/S	0.09%
Manulife Financial Corp.	0.07%
Sumitomo Mitsui Trust Group, Inc.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	89.21%
United Kingdom	4.49%
Individuals	3.15%
Canada	1.72%
Australia	1.6%
Norway	1.07%
France	0.86%
Bermuda	0.51%
Luxembourg	0.5%
Sweden	0.47%
Germany	0.47%
Switzerland	0.43%
Netherlands	0.37%
Denmark	0.24%
Ireland	0.17%
Finland	0.08%
Japan	0.07%
Hong Kong	0.05%
Singapore	0.04%
Spain	0.03%
China	0.03%
Austria	0.02%
United Arab Emirates	0.02%
Belgium	0.01%

Based on 1000 largest holdings

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Employees

1,147

Sector

Biotechnology & Medical Research

Calendar

06:45am - J.P. Morgan Healthcare Conference

More about the company